Radezolid
CAS No. 869884-78-6
Radezolid ( RX-1741 )
产品货号. M26804 CAS No. 869884-78-6
Radezolid 是一种新型恶唑烷酮类抗生素。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥1353 | 有现货 |
|
10MG | ¥2292 | 有现货 |
|
25MG | ¥3912 | 有现货 |
|
50MG | ¥5597 | 有现货 |
|
100MG | ¥7962 | 有现货 |
|
200MG | 获取报价 | 有现货 |
|
500MG | 获取报价 | 有现货 |
|
1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Radezolid
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Radezolid 是一种新型恶唑烷酮类抗生素。
-
产品描述Radezolid is a novel oxazolidinone antibiotic agent.(In Vitro):Radezolid displays a greater potency than linezolid, independent of the bacteria tested, when concentrations are expressed on a weight (mg/L) basis. Radezolid shows an improved potency compared to that of linezolid when concentrations are expressed on a weight (mg/L) basis. Radezolid MICs are systematically equal to or lower (up to 3 log2 dilutions) than those of linezolid for all linezolid-susceptible strains, with an 8-fold difference for the linezolid-resistant strains. Radezolid and TR-700 perform well against 3-copy G2447T, G2576T, and G2576T/T2571C mutants .
-
体外实验Radezolid MICs are systematically equal to or lower (up to 3 log2 dilutions) than those of linezolid for all linezolid-susceptible strains, with an 8-fold difference for the linezolid-resistant strains. Radezolid shows a greater potency than linezolid, independent of the bacteria tested, when concentrations are expressed on a weight (mg/L) basis. Radezolid shows an improved potency compared to that of linezolid when concentrations are expressed on a weight (mg/L) basis. Radezolid and TR-700 perform well against 3-copy G2447T, G2576T, and G2576T/T2571C mutants.
-
体内实验——
-
同义词RX-1741
-
通路GPCR/G Protein
-
靶点Antibacterial
-
受体TNIK
-
研究领域——
-
适应症——
化学信息
-
CAS Number869884-78-6
-
分子量438.463
-
分子式C22H23FN6O3
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : ≥ 25 mg/mL (57.02 mM)
-
SMILESCC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(CNCc2cnn[nH]2)cc1
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Lee Y, et al. Synergistic inhibition effect of TNIK inhibitor KY-05009 and receptor tyrosine kinase inhibitor dovitinib on IL-6-induced proliferation and Wnt signaling pathway in human multiple myeloma cells. Oncotarget. 2017 Jun 20;8(25):41091-41101.
产品手册
关联产品
-
4-Hydroxyquinazoline
一些4-喹唑啉酮衍生物具有抗血小板活性。
-
Sutezolid
一种恶唑烷酮抗生素,在体外和体内具有有效的抗结核活性。
-
N-Butanoyl-L-homoser...
N-丁酰-L-高丝氨酸内酯是一种可裂解的 ADC 连接体,用于合成抗体药物偶联物 (ADC)。